The DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
Aspirin-like Molecules that Covalently Inactivate Cyclooxygenase-2
Abstract
Many of aspirin's therapeutic effects arise from its acetylation of cyclooxygenase-2 (COX-2), whereas its antithrombotic and ulcerogenic effects result from its acetylation of COX-1. Here, aspirin-like molecules were designed that preferentially acetylate and irreversibly inactivate COX-2. The most potent of these compounds was o -(acetoxyphenyl)hept-2-ynyl sulfide (APHS). Relative to aspirin, APHS was 60 times as reactive against COX-2 and 100 times as selective for its inhibition; it also inhibited COX-2 in cultured macrophages and colon cancer cells and in the rat air pouch in vivo. Such compounds may lead to the development of aspirin-like drugs for the treatment or prevention of immunological and proliferative diseases without gastrointestinal or hematologic side effects.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Inhibition of Prostaglandin Synthesis as a Mechanism of Action for Aspirin-like Drugs
VANE, J. R. (1971) · Nature New Biology · doi:10.1038/newbio231232a0 · Cited by 8,605
Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas
Eberhart, C. E., Coffey, R. J., Radhika, A., Giardiello, F. M., Ferrenbach, S., & Dubois, R. N. (1994) · Gastroenterology · doi:10.1016/0016-5085(94)90246-1 · Cited by 2,514
Structural basis for selective inhibition of cyclooxygenase-2 by anti-inflammatory agents
Kurumbail, R. G., Stevens, A. M., Gierse, J. K., McDonald, J. J., Stegeman, R. A., Pak, J. Y., Gildehaus, D., iyashiro, J. M., Penning, T. D., Seibert, K., et al. (1996) · Nature · doi:10.1038/384644a0 · Cited by 1,917
Self-citationSelective inhibition of inducible cyclooxygenase 2 in vivo is antiinflammatory and nonulcerogenic.
Masferrer, J. L., Zweifel, B. S., Manning, P. T., Hauser, S. D., Leahy, K. M., Smith, W. G., Isakson, P. C., & Seibert, K. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.8.3228 · Cited by 1,310
Self-citationThe X-ray crystal structure of the membrane protein prostaglandin H2 synthase-1
Picot, D., Loll, P. J., & Garavito, R. M. (1994) · Nature · doi:10.1038/367243a0 · Cited by 1,265
Acetylation of prostaglandin synthase by aspirin.
Roth, G. J., Stanford, N., & Majerus, P. W. (1975) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.72.8.3073 · Cited by 1,009
Kawamori, T., Rao, C. V., Seibert, K., & Reddy, B. S. (1998) · PubMed · Cited by 916
Self-citationInhibition of human colon cancer cell growth by selective inhibition of cyclooxygenase-2.
Sheng, H., Shao, J., Kirkland, S. C., Isakson, P., Coffey, R. J., Morrow, J., Beauchamp, R. D., & DuBois, R. N. (1997) · Journal of Clinical Investigation · doi:10.1172/jci119400 · Cited by 712
Flexibility of the NSAID binding site in the structure of human cyclooxygenase-2
Luong, C., Miller, A., Barnett, J., Chow, J., Ramesha, C., & Browner, M. F. (1996) · Nature Structural Biology · doi:10.1038/nsb1196-927 · Cited by 618
Mechanism of Action of Anti-Inflammatory Drugs
Vane, J. R., & Botting, R. M. (1996) · Scandinavian Journal of Rheumatology · doi:10.3109/03009749609097226 · Cited by 465
Cited by
The anti-inflammatory agents aspirin and salicylate inhibit the activity of IκB kinase-β
Yin, M.-J., Yamamoto, Y., & Gaynor, R. B. (1998) · Nature · doi:10.1038/23948 · Cited by 1,590
The role of cyclooxygenases in inflammation, cancer, and development
Williams, C. S., Mann, M., & DuBois, R. N. (1999) · Oncogene · doi:10.1038/sj.onc.1203286 · Cited by 1,417
McAdam, B. F., Catella-Lawson, F., Mardini, I. A., Kapoor, S., Lawson, J. A., & FitzGerald, G. A. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.1.272 · Cited by 1,305
Colorectal Cancer: Molecules and Populations
Potter, J. D. (1999) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/91.11.916 · Cited by 881
Nuclear factor-κB inhibitors as sensitizers to anticancer drugs
Nakanishi, C., & Toi, M. (2005) · Nature Reviews Cancer · doi:10.1038/nrc1588 · Cited by 724
Stepan, A. F., Walker, D. P., Bauman, J., Price, D. A., Baillie, T. A., Kalgutkar, A. S., & Aleo, M. D. (2011) · Chemical Research in Toxicology · doi:10.1021/tx200168d · Cited by 698
Self-citationAwtry, E. H., & Loscalzo, J. (2000) · Circulation · doi:10.1161/01.cir.101.10.1206 · Cited by 690
Cyclooxygenase inhibitors – current status and future prospects
Dannhardt, G., & Kiefer, W. (2001) · European Journal of Medicinal Chemistry · doi:10.1016/s0223-5234(01)01197-7 · Cited by 657
Copper complexes of non-steroidal anti-inflammatory drugs: an opportunity yet to be realized
Weder, J. E., Dillon, C. T., Hambley, T. W., Kennedy, B. J., Lay, P. A., Biffin, J. R., Regtop, H. L., & Davies, N. M. (2002) · Coordination Chemistry Reviews · doi:10.1016/s0010-8545(02)00086-3 · Cited by 536
Arachidonic Acid Oxygenation by COX-1 and COX-2
Marnett, L. J., Rowlinson, S. W., Goodwin, D. C., Kalgutkar, A. S., & Lanzo, C. A. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.33.22903 · Cited by 523
Self-citationCyclooxygenase-2—10 Years Later
Hinz, B., & Brune, K. (2002) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.300.2.367 · Cited by 518
Overcoming cancer therapeutic bottleneck by drug repurposing
Zhang, Z., Zhou, L., Xie, N., Nice, E. C., Zhang, T., Cui, Y., & Huang, C. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-00213-8 · Cited by 516
Signalling networks regulating cyclooxygenase-2
Tsatsanis, C., Androulidaki, A., Venihaki, M., & Margioris, A. N. (2006) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2006.03.021 · Cited by 492
The development of COX2 inhibitors
Flower, R. J. (2003) · Nature Reviews Drug Discovery · doi:10.1038/nrd1034 · Cited by 459
Serhan, C. N. (2005) · Prostaglandins, Leukotrienes and Essential Fatty Acids · doi:10.1016/j.plefa.2005.05.002 · Cited by 454
Amir, M., & Shikha, K. (2004) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2004.02.008 · Cited by 373
INHIBITION OF CYCLOOXYGENASE-2 SUPPRESSES ANGIOGENESIS AND THE GROWTH OF PROSTATE CANCER IN VIVO
LIU, X. H., KIRSCHENBAUM, A., YAO, S., LEE, R., HOLLAND, J. F., & LEVINE, A. C. (2000) · Journal of Urology · doi:10.1016/s0022-5347(05)67321-1 · Cited by 363
Kalgutkar, A. S., Marnett, A. B., Crews, B. C., Remmel, R. P., & Marnett, L. J. (2000) · Journal of Medicinal Chemistry · doi:10.1021/jm000004e · Cited by 316
Self-citationCOX-2: A Target for Colon Cancer Prevention
Marnett, L. J., & DuBois, R. N. (2002) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.42.082301.164620 · Cited by 313
Self-citationBhandari, S. V., Bothara, K. G., Raut, M. K., Patil, A. A., Sarkate, A. P., & Mokale, V. J. (2008) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2007.11.014 · Cited by 302
Xu, X., Gu, Z., Chen, X., Shi, C., Liu, C., Liu, M., Wang, L., Sun, M., Zhang, K., Liu, Q., et al. (2019) · Acta Biomaterialia · doi:10.1016/j.actbio.2019.01.001 · Cited by 290
O'Brien, P. J. (2000) · Chemico-Biological Interactions · doi:10.1016/s0009-2797(00)00201-5 · Cited by 258
Langenbach, R., Loftin, C., Lee, C., & Tiano, H. (1999) · Biochemical Pharmacology · doi:10.1016/s0006-2952(99)00158-6 · Cited by 230
LANGENBACH, R., LOFTIN, C. D., LEE, C., & TIANO, H. (1999) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1999.tb08723.x · Cited by 170
Cerella, C., Sobolewski, C., Dicato, M., & Diederich, M. (2010) · Biochemical Pharmacology · doi:10.1016/j.bcp.2010.06.050 · Cited by 129
Sphingolipids in neuroinflammation: a potential target for diagnosis and therapy
Lee, J. Y., Jin, H. K., & Bae, J.-S. (2020) · BMB Reports · doi:10.5483/bmbrep.2020.53.1.278 · Cited by 80
Development of covalent inhibitors: Principle, design, and application in cancer
Zheng, L., Li, Y., Wu, D., Xiao, H., Zheng, S., Wang, G., & Sun, Q. (2023) · MedComm – Oncology · doi:10.1002/mog2.56 · Cited by 71
Covalent modification as a strategy to block protein–protein interactions with small-molecule drugs
Way, J. (2000) · Current Opinion in Chemical Biology · doi:10.1016/s1367-5931(99)00049-6 · Cited by 55
Metadata
- Authors
- Kalgutkar, A. S., Crews, B. C., Rowlinson, S. W., Garner, C., Seibert, K., & Marnett, L. J.
- Venue
- Science
- Published
- 1998-05-22
- Volume
- 280
- Issue
- 5367
- Pages
- 1268-1270
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- OpenAlex
- W2009132110
- Cited by
- 258
- References
- 20
- FWCI
- 17.23
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.